Cargando…

Pre-Clinical Evaluation of the Proteasome Inhibitor Ixazomib against Bortezomib-Resistant Leukemia Cells and Primary Acute Leukemia Cells

At present, 20–30% of children with acute leukemia still relapse from current chemotherapy protocols, underscoring the unmet need for new treatment options, such as proteasome inhibition. Ixazomib (IXA) is an orally available proteasome inhibitor, with an improved safety profile compared to Bortezom...

Descripción completa

Detalles Bibliográficos
Autores principales:	Roeten, Margot S.F., van Meerloo, Johan, Kwidama, Zinia J., ter Huizen, Giovanna, Segerink, Wouter H., Zweegman, Sonja, Kaspers, Gertjan J.L., Jansen, Gerrit, Cloos, Jacqueline
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8002577/ https://www.ncbi.nlm.nih.gov/pubmed/33802801 http://dx.doi.org/10.3390/cells10030665

Ejemplares similares

(Immuno)proteasomes as therapeutic target in acute leukemia
por: Cloos, Jacqueline, et al.
Publicado: (2017)

P329: HIGH IMMUNOPROTEASOME ACTIVITY AS NOVEL INDICATOR FOR SENSITIVITY TO BORTEZOMIB-CONTAINING CHEMOTHERAPY IN ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS FROM CHILDREN’S ONCOLOGY GROUP TRIAL AALL1231
por: Roeten, Margot, et al.
Publicado: (2023)

Exocytosis of polyubiquitinated proteins in bortezomib-resistant leukemia cells: a role for MARCKS in acquired resistance to proteasome inhibitors
por: Franke, Niels E., et al.
Publicado: (2016)

Positioning of proteasome inhibitors in therapy of solid malignancies
por: Roeten, Margot S. F., et al.
Publicado: (2017)

Proteasome subunit expression analysis and chemosensitivity in relapsed paediatric acute leukaemia patients receiving bortezomib-containing chemotherapy
por: Niewerth, Denise, et al.
Publicado: (2016)

Interferon-γ-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines
por: Niewerth, Denise, et al.
Publicado: (2014)

Harnessing Gene Expression Profiles for the Identification of Ex Vivo Drug Response Genes in Pediatric Acute Myeloid Leukemia
por: Cucchi, David G.J., et al.
Publicado: (2020)

Bortezomib resistance in multiple myeloma is associated with increased serine synthesis
por: Zaal, Esther A., et al.
Publicado: (2017)

Feasibility of Long-term Proteasome Inhibition in Multiple Myeloma by in-class Transition From Bortezomib to Ixazomib
por: Manda, Sudhir, et al.
Publicado: (2020)

Structural basis to repurpose boron-based proteasome inhibitors Bortezomib and Ixazomib as β-lactamase inhibitors
por: Perbandt, Markus, et al.
Publicado: (2022)

Glucocorticoid Resistant Pediatric Acute Lymphoblastic Leukemia Samples Display Altered Splicing Profile and Vulnerability to Spliceosome Modulation
por: Sciarrillo, Rocco, et al.
Publicado: (2020)

Pharmacodynamic monitoring of (immuno)proteasome inhibition during bortezomib treatment of a critically ill patient with lupus nephritis and myocarditis
por: de Groot, Karina A, et al.
Publicado: (2015)

Overcoming bortezomib resistance in human B cells by anti-CD20/rituximab-mediated complement-dependent cytotoxicity and epoxyketone-based irreversible proteasome inhibitors
por: Verbrugge, Sue Ellen, et al.
Publicado: (2013)

Statins markedly potentiate aminopeptidase inhibitor activity against (drug-resistant) human acute myeloid leukemia cells
por: Jansen, Gerrit, et al.
Publicado: (2023)

Ixazomib: An Oral Proteasome Inhibitor for the Treatment of Multiple Myeloma
por: Ramirez, Krista G.
Publicado: (2017)

Clinical Pharmacology of Ixazomib: The First Oral Proteasome Inhibitor
por: Gupta, Neeraj, et al.
Publicado: (2018)

Methotrexate resistance in relation to treatment outcome in childhood acute lymphoblastic leukemia
por: Wojtuszkiewicz, Anna, et al.
Publicado: (2015)

Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib
por: Kumar, S K, et al.
Publicado: (2015)

Model‐Informed Drug Development for Ixazomib, an Oral Proteasome Inhibitor
por: Gupta, Neeraj, et al.
Publicado: (2018)

Gene Expression Profiles Associated with Pediatric Relapsed AML
por: Bachas, Costa, et al.
Publicado: (2015)

SF3B1 as therapeutic target in FLT3/ITD positive acute myeloid leukemia
por: van der Werf, Inge, et al.
Publicado: (2021)

Novel proteasome inhibitor ixazomib sensitizes neuroblastoma cells to doxorubicin treatment
por: Li, Haoyu, et al.
Publicado: (2016)

DNA vs cDNA FLT3-ITD allelic ratio and length measurements in adult acute myeloid leukemia
por: Cucchi, David G. J., et al.
Publicado: (2021)

Bortezomib-Based Regimens and Plasma Cell Leukemia
por: Bolaman, Ali Zahit
Publicado: (2021)

Bortezomib Amplifies Effect on Intracellular Proteasomes by Changing Proteasome Structure()
por: Pitcher, David S., et al.
Publicado: (2015)

The resistance mechanisms of proteasome inhibitor bortezomib
por: Lü, Shuqing, et al.
Publicado: (2013)

Successful ixazomib treatment for relapsed and refractory acute myeloid leukemia transformed from myelodysplastic syndrome
por: Oka, Satoko, et al.
Publicado: (2021)

Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies
por: Smith, David C., et al.
Publicado: (2015)

The Proteasome Inhibitor Ixazomib Inhibits the Formation and Growth of Pulmonary and Abdominal Osteosarcoma Metastases in Mice
por: Harris, Michael A., et al.
Publicado: (2020)

Impaired sleep affects quality of life in children during maintenance treatment for acute lymphoblastic leukemia: an exploratory study
por: van Litsenburg, Raphaële RL, et al.
Publicado: (2011)

Ixazomib combined with lenalidomide and dexamethasone chemotherapy for newly diagnosed multiple myeloma in China—Compared with bortezomib/lenalidomide/dexamethasone
por: Huo, Zhongjun, et al.
Publicado: (2022)

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
por: Cloos, Jacqueline, et al.
Publicado: (2018)

Pharmacokinetics of ixazomib, an oral proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairment
por: Gupta, Neeraj, et al.
Publicado: (2016)

Preclinical evaluation of antitumor activity of the proteasome inhibitor MLN2238 (ixazomib) in hepatocellular carcinoma cells
por: Augello, Giuseppa, et al.
Publicado: (2018)

Inhibition of chymotrypsin-like activity of the proteasome by ixazomib prevents mitochondrial dysfunction during myocardial ischemia
por: Sánchez, Gina, et al.
Publicado: (2020)

Nelfinavir augments proteasome inhibition by bortezomib in myeloma cells and overcomes bortezomib and carfilzomib resistance
por: Kraus, M, et al.
Publicado: (2013)

MicroRNA-106b~25 cluster is upregulated in relapsed MLL-rearranged pediatric acute myeloid leukemia
por: Verboon, Lonneke J., et al.
Publicado: (2016)

RONC-21. IDENTIFICATION OF EPIGENETIC DRUGS AS RADIOSENSITIZERS IN PEDIATRIC HIGH-GRADE GLIOMAS
por: Metselaar, Dennis, et al.
Publicado: (2020)

AURKA and PLK1 inhibition selectively and synergistically block cell cycle progression in diffuse midline glioma
por: Metselaar, Dennis S., et al.
Publicado: (2022)

Preclinical efficacy and biological effects of the oral proteasome inhibitor ixazomib in diffuse large B-cell lymphoma
por: Liu, Wei, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_j3t1a9l78bl832sp25m2efaosj